Naloxone Spray Market Report 2026

The naloxone spray market size has grown exponentially in recent years. It will grow from $810.65 billion in 2025 to $1.0 trillion in 2026 at a compound annual growth rate (CAGR) of 24.4%. The growth in the historic period can be attributed to increasing opioid abuse cases, limited emergency response options, reliance on intravenous naloxone, high hospitalization rates due to overdose, government initiatives for opioid crisis.

The naloxone spray market size is expected to see exponential growth in the next few years. It will grow to $2.42 trillion in 2030 at a compound annual growth rate (CAGR) of 24.6%. The growth in the forecast period can be attributed to rising awareness of naloxone nasal sprays, growth in OTC naloxone products, technological advancements in spray delivery systems, expansion of emergency response networks, favorable reimbursement policies. Major trends in the forecast period include rapid adoption of intranasal administration, expansion of over-the-counter availability, rising opioid overdose cases driving demand, development of patient-friendly single-dose formats, integration with emergency response protocols.

The increasing demand for telemedicine is anticipated to support the growth of the naloxone spray market in the coming years. Telemedicine, also known as telehealth, is a method of delivering healthcare services through digital technologies and telecommunications, enabling remote medical consultations and care. By providing quicker, more accessible, and more comprehensive support to individuals at risk of opioid overdose, telemedicine can play a vital role in saving lives and addressing the opioid crisis more effectively. For instance, in April 2023, FAIR Health Inc., a US-based non-profit organization, reported that national telehealth usage increased by 7.3%, rising from 5.5% of medical claim lines in December 2022 to 5.9% in January 2023. Consequently, the growing adoption of telemedicine is contributing to the expansion of the naloxone spray market.

Major companies operating in the naloxone spray market are prioritizing the development of innovative offerings, such as over-the-counter (OTC) naloxone hydrochloride (HCl) nasal sprays, to meet the increasing demand for expanded community access, rapid overdose reversal, and simplified use. Naloxone nasal spray is a needle-free formulation designed for quick intranasal administration, offering greater ease of use and faster deployment compared to conventional injectable naloxone, which generally requires trained healthcare professionals for administration. For instance, in May 2024, Walgreens, a US-based company, announced the launch of Walgreens Brand Naloxone HCl Nasal Spray. This OTC product is intended to rapidly counteract the effects of opioid overdose, providing an essential tool in addressing the opioid epidemic. Naloxone works by blocking opioid effects in the brain, restoring normal breathing and helping prevent death when administered in a timely manner. Despite its proven effectiveness, access to naloxone remains restricted in many communities, highlighting the importance of this launch in enhancing availability and awareness.

In June 2025, Navamedic ASA, a Norway-based specialty pharmaceutical company, acquired DNE Pharma AS for up to USD 22 million. Through this acquisition, Navamedic aims to strengthen its presence in the naloxone spray market and broaden its addiction treatment portfolio by integrating DNE Pharma’s intranasal naloxone product, Ventizolve, along with related opioid-dependence therapies. DNE Pharma AS is a Norway-based pharmaceutical company that develops addiction treatment products, including the Ventizolve naloxone nasal spray used for emergency opioid overdose reversal.

Major companies operating in the naloxone spray market are Emergent BioSolutions Inc., Amphastar Pharmaceuticals Inc., Hikma Pharmaceuticals plc, Indivior plc, Nasus Pharma LLC, Opiant Pharmaceuticals Inc., Pfizer Inc., Samarth Pharma Pvt. Ltd., Teva Pharmaceutical Industries Ltd., Adapt Pharma Inc., Cardinal Health Inc., Kaleo Inc., McKesson Corporation, Mundipharma International Limited, NextDistro Inc., Rite Aid Corporation, Novartis International AG, Sandoz International GmbH, Fresenius Kabi USA LLC, West-Ward Pharmaceuticals Corp., Lupin Ltd.

North America was the largest region in the naloxone spray market in 2025. The regions covered in the naloxone spray market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the naloxone spray market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on imported pharmaceutical ingredients and medical devices have affected the naloxone spray market by increasing production costs and supply chain delays. Segments such as prescription and over-the-counter naloxone sprays are most impacted, particularly in regions like North America and Europe where imports dominate. While costs have risen, tariffs have incentivized local manufacturing and supply diversification, potentially strengthening domestic production capabilities and improving long-term market resilience.

The naloxone spray market research report is one of a series of new reports that provides naloxone spray market statistics, including naloxone spray industry global market size, regional shares, competitors with a naloxone spray market share, detailed naloxone spray market segments, market trends and opportunities, and any further data you may need to thrive in the naloxone spray industry. This naloxone spray market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Naloxone spray is a medication that attaches to opioid receptors and inhibits or reverses the effects of opioids. When administered quickly, naloxone counteracts opioid activity and restores normal breathing. It can be given intravenously or delivered as a nasal spray. Naloxone nasal spray is provided as a liquid solution for intranasal use, with each device containing a single dose intended for one-time administration.

The main dosage strengths available for naloxone spray are 2 mg per actuation and 4 mg per actuation. The 2 mg per actuation formulation delivers an equivalent of 1.8 mg of naloxone and is used as an emergency treatment for confirmed or suspected opioid overdose, characterized by respiratory and/or central nervous system depression. This 2 mg dose is approved for use in opioid-dependent individuals who are at risk of severe opioid withdrawal and who reside in environments with a low risk of accidental or intentional opioid exposure by household contacts. Naloxone sprays are distributed through multiple channels, including hospitals, clinics, retail pharmacies, online pharmacies, and other outlets.

The naloxone spray market consists of sales of injectable and prepackaged nasal spray. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.